A case of severe course of COVID-19 treated with experimental therapy
Authors:
Milan Zlámal 1; Katarína Štěchovská 2; Michal Holub 1
Authors place of work:
Klinika infekčních nemocí 1. LF UK a ÚVN Praha
1; Interní klinika 1. LF UK a ÚVN Praha
2
Published in the journal:
Čas. Lék. čes. 2020; 159: 181-184
Category:
Case Report
Summary
70-year-old high-risk patient with severe course of COVID-19 hospitalized for progressive dyspnea due to extensive bilateral pneumonia caused by SARS-CoV-2. The patient was treated with hydroxychloroquine and azithromycin from day one of hospital stay. Because of progression on the therapy, the convalescent plasma was administered on day three of hospitalization. The patient subsequently improved and was discharged home on day eleven of the hospital stay.
Risk factors of severe course of the infection, complications and potential therapies of COVID-19 are discussed.
Keywords:
SARS-CoV-2 – COVID-19 – viral pneumonia – hydroxychloroquine – azithromycin – blood plasma
Zdroje
-
Cuccinota D, Vanelli M. WHO declares COVID-19 pandemic. Acta Biomed 2020; 91: 157–160.
-
Li B, Yang J, Zhao F et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020; 109: 531–538.
-
Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–1062.
-
Chen T, Wu D, Chen H et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368: m1091.
-
Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science 2020; 367: 1412–1413.
-
Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care 2020; 24: 154.
-
Guan W, Ni Z, Liang W et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720.
-
McGonagle D, Sharif K, O’Regan A et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020; 102537.
-
Ranucci M, Ballotta A, Di Dedda U et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020; 18: 1747–1751.
-
Blackburn WD Jr, Prupas HM, Silverfield JC et al. Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. Arthritis Rheum 1995; 38: 1447–1456.
-
Kümpel P, Holub M, Roháčová H, Plíšek S. Doporučený postup SIL ČLS JEP léčby pacientů s prokázanou infekcí COVID-19. Společnost infekčního lékařství ČLS JEP, 2020. Dostupné na: www.infekce.cz/Covid2019/DP-SIL-covid120520p.pdf
-
Liu J, Cao R, Xu M et al. Hydroxychloroquine, a less toxic chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6: 16.
-
Gautret P, Lagier JC, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56: 105949.
-
Rosenberg ES, Dufort EM, Udo T et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA 2020; 323: 2493–2502.
-
Gilead Sciences statement on expanding global supply of investigational antiviral remdesivir. Dostupné na: www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-remdesivir-global-supply
-
Duan K, Liu B, Li C et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117: 9490–9496.
-
Doporučený postup pro použití rekonvalescentní plazmy v léčbě dospělých pacientů s COVID-19. ČSARIM ČLS JEP, STL ČLS JEP, SIL ČLS JEP, Klinická skupina COVID MZ, 30. 4. 2019. Dostupné na: www.infekce.cz/Covid2019/DPtrf-covid050520.pdf
-
Posuzování způsobilosti k dárcovství krve a krevních složek. Společnost pro transfuzní lékařství ČLS JEP, 2019. Dostupné na: www.transfuznispolecnost.cz/doporucene-postupy/posuzovani-zpusobilosti-k-darcovstvi-krve-a-krevnich-slozek-239
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Production and use of convalescent plasma in COVID-19 treatment, taking into account the experience in the Central Millitary Hospital Prague
- A case of severe course of COVID-19 treated with experimental therapy
- Gambling products and their risk potential for gambling disorder
- Zapomenutý gastroenterolog?